ヒト化マウスモデルの世界市場規模：タイプ別、用途別、エンドユーザー別、地域別、範囲および予測

ヒト化マウスモデルの市場規模と予測

ヒト化マウスモデル市場規模は、2024年には1億2,477万米ドルと評価され、2024年～2031年の間に9.54％のCAGRで成長する見込みで、2031年には2億4,226万米ドルに達すると予測されています。ヒト化マウスモデルとは、ヒトの遺伝子、臓器、免疫系まで含むように遺伝子編集された実験用マウスの一種です。科学者たちは、人間の病気をよりよく理解し、治療法の可能性を生体でテストするために、このマウスを開発します。これらのマウスはヒトに似た形質を持っているため、従来のマウスよりもヒトの体内でどのように病気が進行するかをより効果的に再現することができます。これらは生物医学研究において不可欠なツールであり、人間の生物学や病気の理解に役立つ幅広い用途があります。これらのマウスは、ヒトの遺伝子、組織、細胞を持つように遺伝子改変されており、生体におけるヒト特有の生物学的プロセスを調べるのに理想的です。ヒト化マウスモデルは、主に薬物の研究や試験に用いられています。

ヒト化マウスモデルは、将来の生物医学研究、特に薬剤開発、免疫学、個別化医療において重要な役割を果たすと予測されています。ヒト化マウスモデルは、ヒトの遺伝子、臓器、免疫細胞を持つように遺伝子改変されているため、ヒトの病気を研究したり、管理された環境で潜在的な治療法をテストしたりするのに理想的です。

ヒト化マウスモデルの世界市場力学

主な市場促進要因

個別化医療の進展：

個別化医療の台頭は、ヒト化マウスモデル事業の主要な促進要因です。個別化医療は、個々の患者の遺伝子構成に基づいて治療法をカスタマイズしようとするものであり、ヒト化マウスモデルはこのような場面で非常に有用です。ヒトに似た免疫系や他のヒト遺伝子を持つように設計されたこれらのモデルにより、研究者はヒト特有の疾患を調査し、多様な遺伝的背景に対して異なる治療法がどのように機能するかを探求することができます。

慢性疾患の有病率の増加：

慢性疾患の蔓延は増加の一途をたどっており、それがヒト化マウスモデルの需要を高めています。これらのモデルは、ヒトの生理機能を適切に模倣できないことが多い標準的な動物モデルよりも、ヒトの疾病状態をより正確に把握することができます。例えば、がん研究においては、ヒト化マウスにヒト腫瘍を移植することで、腫瘍の成長、転移、薬に対する反応などを、管理された環境で調べることができます。

遺伝子工学の技術的進歩：

遺伝子工学の技術開発により、ヒト化マウスの作製と有用性が大幅に向上しました。CRISPR/Cas9技術により、遺伝子編集はより容易かつ正確になり、研究者はヒトの生物学に近いモデルを開発できるようになった。このような技術的進歩により、複雑なヒトの病気や薬物反応、免疫系の機能を研究する上で重要な、より洗練された精密なヒト化マウスの開発が可能になった。

主な課題

遺伝子工学における複雑性

ヒト化マウスモデルの開発は、時間と複雑な手順を要します。これらのモデルでは、ヒトの遺伝子、臓器、免疫細胞をマウスにイントロダクションする必要があり、高度な遺伝子工学的手順が必要となります。マウスのゲノムにヒトの要素を挿入し、それらが適切に機能することを確認する手順は困難です。

限られた寿命と繁殖の問題：

ヒト化マウスは寿命が短く、繁殖が難しいという大きな問題があります。ヒトの遺伝子や細胞を組み込んだ結果、免疫系が弱くなったり、その他の健康上の問題が生じたりして、病気にかかりやすくなったり、寿命が短くなったりすることがよくあります。

不完全なヒト化

もうひとつの問題は、ヒト化マウスモデルが必ずしも人間の生物学を完全には表現していないということです。ヒトの免疫反応や疾患プロセスの特徴を模倣することはできても、基本的にはマウスであり、ヒトの生理機能を再現することには限界があります。

主要動向：

遺伝子工学の進歩

注目すべき動向の一つは、遺伝子工学技術の大幅な進歩により、より精密で複雑なヒト化マウスモデルの構築が可能になったことです。CRISPR-Cas9をはじめとする遺伝子編集技術により、科学者はマウスのゲノムを正確に改変し、ヒトの遺伝子、細胞、臓器、さらにはヒトの免疫系全体を含めることができるようになった。

免疫腫瘍学研究における使用の増加

免疫系をがんと闘うためにどのように利用できるかを研究する免疫腫瘍学において、ヒト化マウスモデルの重要性が増しています。これらのモデルは、がん細胞に対する身体の免疫学的反応を高める薬である免疫療法の有効性を評価するのに特に有用です。

感染症研究の拡大

もう一つの動向は、感染症研究、特にHIV、肝炎、最近ではCOVID-19のようなヒト特異的感染症の調査におけるヒト化マウスモデルの使用の増加です。これらのモデルは、典型的な動物モデルでは模倣が困難な、ウイルスがヒトの細胞や免疫系とどのように相互作用するかを学ぶのに重要です。

目次

第1章 世界のヒト化マウスモデル市場のイントロダクション

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 世界のヒト化マウスモデル市場の展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 ヒト化マウスモデルの世界市場：タイプ別

• 概要
• 遺伝子ヒト化マウスモデル
• 細胞ベースヒト化マウスモデル
  • CD34ヒト化マウスモデル（Hu-CD34）
  • PBMCヒト化マウスモデル
  • BLTヒト化マウスモデル

第6章 ヒト化マウスモデルの世界市場：用途別

• 概要
• 腫瘍学
• 免疫・感染症
• 神経科学
• 毒性学
• 造血
• その他

第7章 ヒト化マウスモデルの世界市場：エンドユーザー別

• 概要
• 製薬企業およびバイオテクノロジー企業
• 受託研究機関
• 学術・研究機関

第8章 ヒト化マウスモデルの世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第9章 世界のヒト化マウスモデル市場の競合情勢

• 概要
• 企業市場シェア
• ベンダー情勢
• 主な開発戦略

第10章 企業プロファイル

• The Jackson Laboratory
• Taconic Biosciences, Inc.
• Horizon Discovery Group PLC
• Genoway S.A.
• Harbour Antibodies Bv（A Subsidiary of Harbour Biomed）
• Humurine Technologies
• Vitalstar Biotechnology Co., Ltd.
• Ingenious Targeting Laboratory
• Axenis S.A.S
• Trans Genic, Inc.

第11章 付録

• 関連レポート

Humanized Mouse Model Market Size And Forecast

Humanized Mouse Model Market size was valued at USD 124.77 Million in 2024 and is projected to reach USD 242.26 Million by 2031 , growing at a CAGR of 9.54% from 2024 to 2031. A humanized mouse model is a sort of laboratory mouse that has been genetically edited to contain human genes, organs, and even an immune system. Scientists develop these mice to better understand human ailments and test potential remedies in a living organism. Since these mice have human-like traits, they can more effectively replicate how a sickness might progress in a human body than conventional mice. These are essential tools in biomedical research, with a wide range of applications that help us understand human biology and illness. These mice are genetically modified to carry human genes, tissues, or cells, making them ideal for investigating human-specific biological processes in living organisms. Humanized mouse models are mostly used in medication research and testing.

Humanized mouse models are predicted to play an important role in future biomedical research, particularly in drug development, immunology, and personalized medicine. Humanized mouse models are genetically modified to carry human genes, organs, or immune cells making them ideal for studying human diseases and testing potential treatments in a controlled setting.

Global Humanized Mouse Model Market Dynamics

The key market dynamics that are shaping the global humanized mouse model market include:

Key Market Drivers:

Advances in Personalized Medicine:

The rise of personalized medicine is a major driver of the humanized mouse model business. Personalized medicine seeks to customize therapies for individual patients based on their genetic makeup, and humanized mouse models are extremely useful in this setting. These models which are designed to have human-like immune systems or other human genes, enable researchers to investigate human-specific diseases and explore how different treatments might function on diverse genetic backgrounds.

Increasing Prevalence of Chronic Diseases:

Chronic disease prevalence is increasing which is fuelling demand for humanized mouse models. These models offer a more accurate picture of human disease states than standard animal models which frequently fail to properly imitate human physiology. For example, in cancer research, humanized mice can be implanted with human tumors allowing scientists to examine tumor growth, metastasis, and response to medicines in a controlled setting.

Technological Advancements in Genetic Engineering:

Technological developments in genetic engineering have greatly improved the generation and utility of humanized mouse models. CRISPR/Cas9 techniques have made gene editing easier and more precise allowing researchers to develop models that closely match human biology. These technical advancements enable the development of more sophisticated and precise humanized mice which are critical for researching complex human diseases, medication reactions, and immune system functioning.

Key Challenges:

Complexity in Genetic Engineering

: Developing humanized mouse models is a time-consuming and complex procedure. These models necessitate the introduction of human genes, organs, or immune cells into mice which requires advanced genetic engineering procedures. The procedure of inserting human elements into the mouse genome and ensuring that they work properly is difficult.

Limited Lifespan and Reproduction Issues:

Humanized mice have a short lifetime and have difficulty reproducing which presents a big problem. The integration of human genes or cells frequently results in mice with weakened immune systems or other health issues rendering them more susceptible to disease and shortening their lifespan.

Incomplete Humanization

: Another issue is that humanized mouse models are frequently not completely representative of human biology. While they can mimic some features of human immune responses or disease processes, they are still fundamentally mice with limitations in their ability to duplicate human physiology.

Key Trends:

Advances in Genetic Engineering

: One noteworthy trend is the substantial advancement of genetic engineering techniques making it possible to construct more precise and complex humanized mouse models. CRISPR-Cas9 and other gene-editing technologies enable scientists to accurately alter mouse genomes to include human genes, cells, organs, and even entire human immune systems.

Increasing Use in Immuno-Oncology Research

. Humanized mouse models are becoming increasingly significant in immuno-oncology which studies how the immune system might be used to combat cancer. These models are especially useful for assessing the efficacy of immunotherapies which are medicines that increase the body's immunological response to cancer cells.

Expansion in Infectious Disease Research

: Another trend is the increased use of humanized mouse models in infectious disease research, particularly for researching human-specific infections such as HIV, hepatitis, and, most recently, COVID-19. These models are critical for learning how viruses interact with human cells and immune systems which is challenging to mimic using typical animal models.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Humanized Mouse Model Market Regional Analysis

Here is a more detailed regional analysis of the global humanized mouse model market:

North America:

North America dominates the humanized mouse model market owing to its strong research infrastructure and large investments in biomedical research. This supremacy is anticipated to persist in the next years, thanks to several major drivers. The first key driver of the humanized mouse model market in North America is the rising prevalence of chronic illnesses and cancer.

According to the Centers for Disease Control and Prevention (CDC), by 2021, 6 out of 10 adults in the United States will have a chronic disease with 4 out of 10 having two or more. Cancer, in particular, remains a major problem with the National Cancer Institute predicting 1,958,310 new cases in the United States by 2023.

The National Institutes of Health (NIH), the world's largest public supporter of biomedical research has a USD 45 Billion budget for fiscal year 2023 including a considerable amount dedicated to animal model research. Furthermore, the US Food and Drug Administration (FDA) has advocated for the use of humanized mouse models in preclinical investigations to better the translation of research findings into human applications.

Asia Pacific:

The Asia Pacific region is experiencing the quickest growth in the humanized mouse model market owing to significant advances in biomedical research and increased investments in healthcare infrastructure. This fast expansion is fueled by the region's booming pharmaceutical and biotechnology sectors as well as a growing emphasis on individualized medicine.

Chronic diseases such as cancer and autoimmune disorders have become increasingly common in the region. According to the World Health Organization, cancer is the biggest cause of death in Asia Pacific accounting for an estimated 8.8 million new cases and 5.5 million deaths in 2018. This has resulted in a greater desire for more efficient drug research and development processes with humanized mouse models playing an important role.

Asia Pacific's pharmaceutical and biotechnology industry have expanded rapidly. According to the Japan Pharmaceutical Manufacturers Association, the Japanese pharmaceutical market was valued at around 10.7 trillion yen (USD 98 Billion) in 2020 making it the world's third-largest market. This expansion has increased the demand for improved preclinical research tools, such as humanized mouse models.

Global Humanized Mouse Model Market: Segmentation Analysis

The Global Humanized Mouse Model Market is segmented based on Type, Application, End-User, and Geography.

Humanized Mouse Model Market, By Type

• Genetic Humanized Mouse Model
• Cell-Based Humanized Mouse Model
• CD34 Humanized Mouse Model (Hu-CD34)
• PBMC Humanized Mouse Model
• BLT Humanized Mouse Model

Based on the Type, the Global Humanized Mouse Model Market is bifurcated into Genetic Humanized Mouse Model, Cell-Based Humanized Mouse Model, CD34 Humanized Mouse Model (Hu-CD34), PBMC Humanized Mouse Model, and BLT Humanized Mouse Model. The genetic humanized mouse model is currently dominant in the global humanized mouse model market. This dominance is due to the model's advanced capability to replicate human-specific genes within the mouse genome providing researchers with a powerful tool to study human diseases, particularly in genetics and drug development. These models are essential for understanding gene function, and disease mechanisms, and for testing new therapies in a more human-relevant context.

Humanized Mouse Model Market, By Application

• Immunology and Infectious Diseases
• Neuroscience
• Oncology
• Haematopoiesis
• Toxicology
• Others

Based on the Application, the Global Humanized Mouse Model Market is bifurcated into Immunology and Infectious Diseases, Neuroscience, Oncology, Haematopoiesis, Toxicology, and Others. Oncology is the dominant application in the global humanized mouse model market. This dominance is driven by the critical role these models play in cancer research, particularly in the development of immunotherapies. Humanized mouse models are invaluable for studying human tumor growth and testing new cancer treatments, especially those targeting the immune system.

Humanized Mouse Model Market, By End-User

• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations
• Academic & Research Institutions

Based on the End-User, the Global Humanized Mouse Model Market is bifurcated into Pharmaceutical & Biotechnology Companies, Contract Research Organizations, and Academic & Research Institutions. Pharmaceutical & biotechnology companies are the dominant end users in the global humanized mouse model market. This dominance is driven by their extensive use of these models for drug discovery, development, and testing. Humanized mouse models are crucial for evaluating the efficacy and safety of new drugs, particularly those targeting complex human diseases and conditions. These companies rely on humanized mice to simulate human biological responses and predict how new therapies will perform in clinical trials.

Humanized Mouse Model Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on Geography, the Global Humanized Mouse Model Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. North America is the dominant region in the global humanized mouse model market. This dominance is due to the region's advanced research infrastructure, high level of investment in biomedical research, and strong presence of major biotechnology and pharmaceutical companies. North America, particularly the United States leads in the development and adoption of innovative research technologies including humanized mouse models.

Key Players

• The "Global Humanized Mouse Model Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• The Jackson Laboratory, Taconic Biosciences, Inc., Horizon Discovery Group PLC, Genoway S.A., Harbour Antibodies Bv (A Subsidiary of Harbour Biomed), Humurine Technologies, Vitalstar Biotechnology Co., Ltd., Ingenious Targeting Laboratory, Axenis S.A.S, Trans Genic, Inc., Champions Oncology, Inc., Crown Bioscience, Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Humanized Mouse Model Market Key Developments

• In January 2020, Taconic Biosciences, a global pioneer in developing drug discovery animal models, established a new model generation facility in Leverkusen, Germany. This complex, which replaces the previous Taconic facility in Cologne, Germany, houses model generation services.
• In January 2021, Champions Cancer, Inc., a leading worldwide cancer technology business that is redefining drug discovery and development with data-driven research techniques, today announced the expansion of their Lumin Bioinformatics SaaS program.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL HUMANIZED MOUSE MODEL MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL HUMANIZED MOUSE MODEL MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL HUMANIZED MOUSE MODEL MARKET, BY TYPE

• 5.1 Overview
• 5.2 Genetic Humanized Mouse Model
• 5.3 Cell-Based Humanized Mouse Model
  • 5.3.1 CD34 Humanized Mouse Model (Hu-CD34)
  • 5.3.2 PBMC Humanized Mouse Model
  • 5.3.3 BLT Humanized Mouse Model

6 GLOBAL HUMANIZED MOUSE MODEL MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Oncology
• 6.3 Immunology and infectious diseases
• 6.4 Neurosciences
• 6.5 Toxicology
• 6.6 Hematopoiesis
• 6.7 Others

7 GLOBAL HUMANIZED MOUSE MODEL MARKET, BY END-USER

• 7.1 Overview
• 7.2 Pharmaceutical and Biotechnology Companies
• 7.3 Contract Research Organizations
• 7.4 Academic and Research Institutions

8 GLOBAL HUMANIZED MOUSE MODEL MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East And Africa

9 GLOBAL HUMANIZED MOUSE MODEL MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Share
• 9.3 Vendor Landscape
• 9.4 Key Development Strategies

10 COMPANY PROFILES

• 10.1 The Jackson Laboratory
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Taconic Biosciences, Inc.
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Horizon Discovery Group PLC
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Genoway S.A.
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Harbour Antibodies Bv (A Subsidiary of Harbour Biomed)
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Humurine Technologies
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Vitalstar Biotechnology Co., Ltd.
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Ingenious Targeting Laboratory
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Axenis S.A.S
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Trans Genic, Inc.
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 Appendix

• 11.1 Related Reports